Tag: evolocumab

EBBINGHAUS trial shows non-inferiority of evolocumab for cognitive function in cardiovascular...

Amgen has announced detailed results from the evolocumab (Repatha) cognitive function trial (EBBINGHAUS) evaluating the impact on cognitive function in 1,974 patients enrolled in...

ACC 2017: PCSK9 inhibitor evolocumab significantly reduces the risk of cardiovascular...

Data for a new drug that inhibits proprotein convertase subtilisin-kexin type 9 (PCSK9) show that it is associated with a near 60% reduction in...

Evolocumab significantly reduces risk of cardiovascular events

The FOURIER trial evaluating whether evolocumab (Repatha, Amgen) reduces the risk of cardiovascular events in patients with clinically evident atherosclerotic cardiovascular disease (ASCVD) has...

Positive top-line results from phase 3 GLAGOV imaging study of evolocumab

The Phase 3 GLAGOV (Global assessment of plaque regression with a PCSK9 antibody as measured by intravascular iltrasound) trial has met both its primary...